Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T‐cell leukemia/lymphoma

• Material Type: 博士論文
• Title: Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T‐cell leukemia/lymphoma
• Author/Editor: Morichika, Kazuho; 森近, 一穂
• Author Heading: Morichika, Kazuho; 森近, 一穂
• Publication, Distribution, etc.: University of the Ryukyus
• Publication Date: 2019-06-25
• Publication Date (W3CDTF): 2019-06-25
• Periodical title: Cancer Science
• No. or year of volume/issue: 110 9
• Volume: 110
• Issue: 9
• Pages: 2982-2991
• ISSN (Periodical Title): ISSN : 1347-9032; ISSN : 1349-7006
• Degree grantor/type: 琉球大学
• Date Granted: 2020-03-24
• Dissertation Number: 甲第501号
• Degree Type: 博士(医学)
• Text Language Code: eng
• Subject Heading: adult T‐cell leukemia/lymphoma; immunohistochemistry; phosphorylated STAT3; Shimoyama classification; STAT3 mutation
• Target Audience: 一般
• Note (General): Adult T‐cell leukemia/lymphoma (ATLL) is a mature T‐cell neoplasm, and is divided into 2 indolent (smoldering and chronic) and 2 aggressive (acute and lymphoma) clinical subtypes. Based on previous integrated molecular analyses suggesting the importance of the JAK‐STAT pathway in ATLL, we attempted to clarify the clinicopathological significance of this pathway. Clinical and morphological findings were reviewed in 116 cases with ATLL. The nuclear localizations of phosphorylated STAT3 (pSTAT3), pSTAT5, and pSTAT6 were analyzed by immunohistochemistry. Targeted sequencing was undertaken on the portion of STAT3 encoding the Src homology 2 domain. Expression of pSTAT3 was observed in 43% (50/116) of ATLL cases, whereas pSTAT5 and pSTAT6 were largely undetected. Cases with the lymphoma type showed significantly less frequent pSTAT3 expression (8/45, 18%) than those with the other subtypes (41/66, 62%; P < .001). STAT3 mutations were detected in 36% (10/28) and 19% (12/64) of cases with the smoldering and aggressive types of ATLL, respectively. The correlation between STAT3 mutation and pSTAT3 expression was not significant (P = .07). Both univariate and multivariate analysis revealed that pSTAT3 expression was significantly associated with better overall survival and progression‐free survival in the smoldering type of ATLL, whereas STAT3 mutation was not related to a line of clinical outcome. Collectively, our data show that only the lymphoma type showed a low prevalence of tumor cells positive for pSTAT3 expression, and raises the possibility that pSTAT3 expression is a novel biomarker to predict better prognosis in the smoldering type of ATLL.; 学位論文
• Access Restrictions: インターネット公開
• Rights (production): © 2019 The Authors Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.; Creat ive Commo ns Attri bution-NonCo mmercial License; https://creativecommons.org/licenses/by-nc/4.0/
• Related Material (DOI): 10.1111/cas.14114
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 琉球大学 : 琉球大学学術リポジトリ

Table of Contents

https://u-ryukyu.repo.nii.ac.jp/record/2012590/files/iken501review.pdf other

https://u-ryukyu.repo.nii.ac.jp/record/2012590/files/iken501text.pdf fulltext

https://u-ryukyu.repo.nii.ac.jp/record/2012590/files/iken501abstract.pdf abstract